Manuel Hidalgo

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial

  medRxiv · 2025-12-15

• TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

  Journal of Clinical Oncology · 2025-11-04 · 2 citations

• 539 - ÍNDICE DE DESARROLLO HUMANO Y LETALIDAD POR DENGUE EN LA REGIÓN DE LAS AMÉRICAS

  Gaceta Sanitaria · 2025-09-01

• 2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)

  Annals of Oncology · 2025-09-01 · 1 citations

• Non-canonical ALK7 pathways promote pancreatic cancer metastasis through β-catenin/MMP-mediated basement membrane breakdown and intravasation

  Molecular Cancer · 2025-07-04 · 9 citations

• Shaping research in marine functional connectivity for more integrated and effective marine science and managementPreprint

  HAL (Le Centre pour la Communication Scientifique Directe) · 2025-06-13

• Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205).

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

• A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.

  Journal of Clinical Oncology · 2025-05-28

• Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.

  Journal of Clinical Oncology · 2025-01-27 · 2 citations

• Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update.

  Journal of Clinical Oncology · 2025-01-27 · 13 citations

• Supplementary Table S2 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  2025-01-17

• Supplementary Table S5 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  2025-01-17

• Supplementary Table S3 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  2025-01-17

• Supplementary Table S4 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  2025-01-17

• Supplementary Table S1 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  2025-01-17

• Data from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR TrialPreprint

  2025-01-17 · 1 citations

• Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer

  ACS Applied Materials & Interfaces · 2025-01-02 · 26 citations

• Exploring the interplay between the complement system and immune infiltration in pancreatic cancer prognosis

  Pancreatology · 2024-12-01

• A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

  Clinical Cancer Research · 2024-11-14 · 12 citations